Literature DB >> 19030521

Perspectives in psychopharmacology: spotlight on atomoxetine.

Adil Virani1.   

Abstract

Entities:  

Year:  2005        PMID： 19030521      PMCID： PMC2553224     

Source DB:  PubMed          Journal:  Can Child Adolesc Psychiatr Rev        ISSN： 1716-9119


× No keyword cloud information.
  11 in total

1.  Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

Authors:  Christopher J Kratochvil; Jeffrey H Newcorn; L Eugene Arnold; David Duesenberg; Graham J Emslie; Humberto Quintana; Elias H Sarkis; Karen Dineen Wagner; Haitao Gao; David Michelson; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-09       Impact factor: 8.829

2.  A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

Authors:  Margaret Weiss; Rosemary Tannock; Christopher Kratochvil; David Dunn; Jesus Velez-Borras; Christine Thomason; Roy Tamura; Douglas Kelsey; Linda Stevens; Albert J Allen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-07       Impact factor: 8.829

3.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

4.  Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; John H Heiligenstein; Douglas E Faries; Nora Galil; Ralf Dittmann; Graham J Emslie; Christopher J Kratochvil; Harry F Laws; Kory J Schuh
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

Review 5.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

6.  Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

Authors:  Christopher J Kratochvil; John H Heiligenstein; Ralf Dittmann; Thomas J Spencer; Joseph Biederman; Joachim Wernicke; Jeffrey H Newcorn; Charles Casat; Denai Milton; David Michelson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-07       Impact factor: 8.829

7.  Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Authors:  Douglas K Kelsey; Calvin R Sumner; Charles D Casat; Daniel L Coury; Humberto Quintana; Keith E Saylor; Virginia K Sutton; Jill Gonzales; Sandra K Malcolm; Kory J Schuh; Albert J Allen
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

8.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

9.  Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Authors:  Thomas Spencer; John H Heiligenstein; Joseph Biederman; Douglas E Faries; Christopher J Kratochvil; C Keith Conners; William Z Potter
Journal:  J Clin Psychiatry       Date:  2002-12       Impact factor: 4.384

10.  Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.

Authors:  David Michelson; Jan K Buitelaar; Marina Danckaerts; Christopher Gillberg; Thomas J Spencer; Alessandro Zuddas; Douglas E Faries; Shuyu Zhang; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-07       Impact factor: 8.829
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.